921 related articles for article (PubMed ID: 35149146)
1. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
2. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
3. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
4. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
Ruppel KE; Fricke S; Köhl U; Schmiedel D
Front Immunol; 2022; 13():822298. PubMed ID: 35371071
[TBL] [Abstract][Full Text] [Related]
5. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
6. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
7. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
8. Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells.
Cao H; Sugimura R
Cancer Treat Res; 2022; 183():255-274. PubMed ID: 35551663
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
Zhang C; Hu Y; Xiao W; Tian Z
Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
11. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T; Yu SK; Xiang Y; Lu KH; Sun M
Front Immunol; 2022; 13():936496. PubMed ID: 35903099
[TBL] [Abstract][Full Text] [Related]
12. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.
Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z
Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341
[TBL] [Abstract][Full Text] [Related]
13. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients.
Lu SJ; Feng Q
Stem Cells Transl Med; 2021 Nov; 10 Suppl 2(Suppl 2):S10-S17. PubMed ID: 34724715
[TBL] [Abstract][Full Text] [Related]
14. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S
Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.
Dash CP; Sonowal D; Dhaka P; Yadav R; Chettri D; Satapathy BP; Sheoran P; Uttam V; Jain M; Jain A
Front Immunol; 2024; 15():1390498. PubMed ID: 38694508
[TBL] [Abstract][Full Text] [Related]
17. Next Generation Natural Killer Cells for Cancer Immunotherapy.
Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
Front Immunol; 2022; 13():886429. PubMed ID: 35720306
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
Martínez Bedoya D; Dutoit V; Migliorini D
Front Immunol; 2021; 12():640082. PubMed ID: 33746981
[TBL] [Abstract][Full Text] [Related]
20. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
